These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 32546030)

  • 1. The efficacy and safety of CYP2C19 genotype-guided antiplatelet therapy compared with conventional antiplatelet therapy in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials.
    Lyu SQ; Yang YM; Zhu J; Wang J; Wu S; Zhang H; Shao XH; Ren JM
    Platelets; 2020 Nov; 31(8):971-980. PubMed ID: 32546030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genotype-guided antiplatelet therapy compared with conventional therapy for patients with acute coronary syndromes: a systematic review and meta-analysis.
    Zheng L; Yang C; Xiang L; Hao Z
    Biomarkers; 2019 Sep; 24(6):517-523. PubMed ID: 31215825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of major adverse cardiovascular events of
    Biswas M; Kali MSK; Biswas TK; Ibrahim B
    Platelets; 2021 Jul; 32(5):591-600. PubMed ID: 32664772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genotype-Guided Antiplatelet Therapy Versus Standard Therapy for Patients with Coronary Artery Disease: An Updated Systematic Review and Meta-Analysis.
    Tang B; Wang X; Wang X; Liu L; Ma Z
    J Pharm Pharm Sci; 2022; 25():9-23. PubMed ID: 34995471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP2C19 pharmacogenetics versus standard of care dosing for selecting antiplatelet therapy in patients with coronary artery disease: A meta-analysis of randomized clinical trials.
    Kheiri B; Osman M; Abdalla A; Haykal T; Pandrangi PV; Chahine A; Ahmed S; Osman K; Bachuwa G; Hassan M; Bhatt DL
    Catheter Cardiovasc Interv; 2019 Jun; 93(7):1246-1252. PubMed ID: 30403317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genotype-guided antiplatelet therapy compared with standard therapy for patients with acute coronary syndromes or undergoing percutaneous coronary intervention: A systematic review and meta-analysis.
    Wang X; Wang S; Yang J; Yu X; Liu L
    Thromb Res; 2020 Sep; 193():130-138. PubMed ID: 32559569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genotype-guided personalization of antiplatelet treatment: A meta-analysis of patients with ACS or undergoing PCI.
    Liu J; Qin L; Xi S; Tong W; Yuan M; Peng L; Liu J; Wang X; Zhang Y; Yin T
    Thromb Res; 2019 Jul; 179():87-94. PubMed ID: 31100633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial.
    Pereira NL; Farkouh ME; So D; Lennon R; Geller N; Mathew V; Bell M; Bae JH; Jeong MH; Chavez I; Gordon P; Abbott JD; Cagin C; Baudhuin L; Fu YP; Goodman SG; Hasan A; Iturriaga E; Lerman A; Sidhu M; Tanguay JF; Wang L; Weinshilboum R; Welsh R; Rosenberg Y; Bailey K; Rihal C
    JAMA; 2020 Aug; 324(8):761-771. PubMed ID: 32840598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Personalized antiplatelet therapy in patients with coronary artery disease undergoing percutaneous coronary intervention: A network meta-analysis of randomized clinical trials.
    Kheiri B; Abdalla A; Osman M; Barbarawi M; Zayed Y; Haykal T; Chahine A; Bachuwa G; Hassan M; Bhatt DL
    Catheter Cardiovasc Interv; 2019 Aug; 94(2):181-186. PubMed ID: 30628754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic Evaluations of CYP2C19 Genotype-Guided Antiplatelet Therapy Compared to the Universal Use of Antiplatelets in Patients With Acute Coronary Syndrome: A Systematic Review.
    AlMukdad S; Elewa H; Al-Badriyeh D
    J Cardiovasc Pharmacol Ther; 2020 May; 25(3):201-211. PubMed ID: 32027168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-Dose Clopidogrel versus Ticagrelor in CYP2C19 intermediate or poor metabolizers after percutaneous coronary intervention: A Meta-Analysis of Randomized Trials.
    Sheng XY; An HJ; He YY; Ye YF; Zhao JL; Li S
    J Clin Pharm Ther; 2022 Aug; 47(8):1112-1121. PubMed ID: 35396752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of individualized antiplatelet therapy based on CYP2C19 genotype and platelet function on the prognosis of patients after PCI.
    Zhang M; Wang JR; Zhang Y; Zhang P; Ren MY; Jia XM; Ma LP; Gao M; Hou YL
    Eur Rev Med Pharmacol Sci; 2020 Oct; 24(20):10753-10768. PubMed ID: 33155236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis.
    Jiang M; You JH
    Cardiovasc Drugs Ther; 2017 Feb; 31(1):39-49. PubMed ID: 27924429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The contribution of genotype-guided selection of P2Y
    Wu Y; Yu D; Zhang L; Wu Y; Shu B; Ma L; Shi T
    Eur J Clin Pharmacol; 2023 Sep; 79(9):1249-1259. PubMed ID: 37449992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study.
    Ogawa H; Isshiki T; Kimura T; Yokoi H; Nanto S; Takayama M; Kitagawa K; Nishikawa M; Miyazaki S; Ikeda Y; Nakamura M; Tanaka Y; Saito S
    J Cardiol; 2016 Jul; 68(1):29-36. PubMed ID: 26521100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection After Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
    Malik AH; Gupta R; Chakraborty S; Mahajan P; Bandyopadhyay D; Yandrapalli S; Zaid S; Sreenivasan J; Chaturvedi A; Mehta SS; Vyas AV; Patel NC; Combs WG; Ahmad H
    Cardiovasc Revasc Med; 2022 Aug; 41():115-121. PubMed ID: 35033458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective
    Tuteja S; Glick H; Matthai W; Nachamkin I; Nathan A; Monono K; Carcuffe C; Maslowski K; Chang G; Kobayashi T; Anwaruddin S; Hirshfeld J; Wilensky RL; Herrmann HC; Kolansky DM; Rader DJ; Giri J
    Circ Genom Precis Med; 2020 Feb; 13(1):e002640. PubMed ID: 31928229
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Tunehag KR; Thomas CD; Franchi F; Rossi JS; Keeley EC; Anderson RD; Beitelshees AL; Duarte JD; Gong Y; Kerensky RA; McDonough CW; Nguyen AB; Ortega-Paz L; Venkatesh S; Wang Y; Johnson JA; Winterstein AG; Stouffer GA; Angiolillo DJ; Cavallari LH; Lee CR
    J Am Heart Assoc; 2024 Jun; 13(12):e033791. PubMed ID: 38874073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Utility of CYP2C19 Genotyping to Guide Antiplatelet Therapy in Patients With an Acute Coronary Syndrome or Undergoing Percutaneous Coronary Intervention.
    Klein MD; Williams AK; Lee CR; Stouffer GA
    Arterioscler Thromb Vasc Biol; 2019 Apr; 39(4):647-652. PubMed ID: 30760018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of high-dose clopidogrel according to CYP2C19*2 genotype in patients undergoing percutaneous coronary intervention- a systematic review and meta-analysis.
    Zhang L; Yang J; Zhu X; Wang X; Peng L; Li X; Cheng P; Yin T
    Thromb Res; 2015 Mar; 135(3):449-58. PubMed ID: 25511576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.